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Background: In sub-Saharan Africa, malaria continues to cause over 10,000 maternal deaths and 75,000 to 200,000
infant deaths. Successful control of malaria in pregnancy could save lives of mothers and babies and is an essential
part of antenatal care in endemic areas. The primary objective is to determine the protective efficacy of
community-scheduled screening and treatment (CSST) using community health workers (CHW) against the primary
outcome of prevalence of placental malaria. The secondary objectives are to determine the protective efficacy of
CSST on maternal anaemia, maternal peripheral infection, low birth weight, selection of sulfadoxine-pyrimethamine
(SP) resistance markers, and on antenatal clinic (ANC) attendance and coverage of intermittent preventive treatment
during pregnancy (IPTp-SP).
Methods/design: This is a multi-centre cluster-randomised controlled trial involving three countries with
varying malaria endemicity; low (The Gambia) versus high transmission (Burkina Faso and Benin), and varying
degrees of SP resistance (high in Benin and moderate in Gambia and Burkina Faso). CHW and their related
catchment population who are randomised into the intervention arm will receive specific training on
community-based case management of malaria in pregnancy. All women in both study arms will be enrolled
at their first ANC visits in their second trimester where they will receive their first dose of IPTp-SP. Thereafter,
CHW in the intervention arm will perform scheduled monthly screening and treatment in the womens
homes. At time of delivery, a placental biopsy will be collected from all women to determine placental
malaria. At each contact point, filter paper and blood slides will be collected for detection of malaria
infection and SP resistance markers.
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Discussion: To reach successful global malaria control, there is an urgent need to access those at greatest risk of
malaria infection. The project is designed to develop a low-cost intervention in pregnant women which will have
an immediate impact on the malaria burden in resource-limited countries. This will be done by adding to the
standard IPTp-SP delivered through the health facilities: an “extension” strategy to the communities in rural areas
thus bringing health services closer to where women live.
Trial registration: Current Controlled Trials: ISRCTN37259296 (5 July 2013), and clinicaltrials.gov: NCT01941264
(10 September 2013).
Keywords: Malaria, Pregnancy, Community based treatment, Rapid diagnostic tests, Sulfadoxine-pyrimethamine,
Sub-Saharan Africa, Artemether-lumefantrineBackground
Malaria infection remains a major public health problem
in (sub) tropical regions throughout the world. Approxi-
mately half of the world’s population is at risk of malaria
and every year this leads to about 207 million clinical
malaria cases [1].
In endemic countries, pregnant women have a higher
risk of malaria compared to other adults due to the
physiological hormonal changes and reduced immunity.
In areas of stable, moderate to intense transmission,
Plasmodium falciparum infection in pregnancy is often
asymptomatic, yet it is an important contributor to ma-
ternal morbidity, preterm delivery, perinatal morbidity
and mortality [2,3] and may be associated with an in-
creased risk of post-partum haemorrhage [4]. In areas of
low, often unstable, transmission, malaria infection can
evolve towards severe disease and result in maternal
and foetal death. Such adverse outcomes are more fre-
quent in primigravidae [5], in HIV-infected women [6]
or in those from non-endemic countries as they do not
have any immunity acquired before pregnancy [7]. The
increased susceptibility of pregnant women to infection,
and most specifically of primigravidae, is explained by the
sequestration of P. falciparum in the placenta due to its
affinity with the chondroitin sulphate A receptor. Placen-
tal malaria causes intrauterine growth retardation and the
delivery of low birth weight babies who have a significantly
higher risk of dying before their first birthday due to the
reduced transfer of essential nutrients to the developing
foetus as a result of the placental infection [7].
In sub-Saharan Africa, over 30 million women living
in malaria endemic areas become pregnant each year
[8], with malaria causing an estimated >10,000 maternal
deaths and 75,000 to 200,000 infant deaths. In addition,
it is responsible for 2 to 15% of maternal anaemia cases
and up to 14% of low birth weight babies resulting in
poor growth and development [9]. Furthermore, increas-
ing evidence shows that placental malaria per se is associ-
ated with an increased risk of malaria infection and
anaemia in the first and second year of life of the infant
[10,11], possibly mediated by the exposure to blood-stagemalaria antigens in utero and the acquisition of a tolerant
phenotype that persists into childhood [12]. Importantly,
these effects are independent of low birth weight; that is,
they can occur in any child born to mothers with placental
malaria, and seem to be more pronounced in multigrav-
idae [10]. If these observations are confirmed, the burden
of malaria in African pregnant women would extend be-
yond that observed in primigravidae and could be vastly
underestimated.
Successful control of malaria in pregnancy could save
lives of mothers and babies and is an essential part of
antenatal care in endemic areas [2,3]. For sub-Saharan
Africa, the World Health Organization has developed
guidelines for the control of malaria in pregnancy con-
sisting of a three-pronged approach:
1) Prompt and effective management of uncomplicated
malaria in the second and third trimester with
artemisinin-based combination therapy. For the first
trimester, it is recommended to combine quinine
with clindamycin [13].
2) Long-lasting insecticidal bed nets for all pregnant
women in malaria-endemic countries [14].
3) Intermittent preventive treatment during pregnancy
with sulfadoxine-pyrimethamine (IPTp-SP) at regular
intervals during pregnancy [15]. This is a simple,
pragmatic policy that has proven very valuable in
areas with stable, moderate to high malaria
transmission. SP is safe when given in the second
and third trimester of pregnancy, widely available,
cheap and well tolerated. IPTp-SP can clear any
existing malaria infection and provides post-treatment
prophylaxis for a certain period of time, depending on
SP sensitivity of local parasites [2].
Unfortunately, the coverage of long-lasting insecticidal
bed nets and IPTp-SP in many sub-Saharan African coun-
tries remains low [14,16], particularly in peripheral areas
with difficult access to health facilities, leaving certain
remote, poor populations out of reach of basic services.
To add further complexities, SP resistance is increasing
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or additional efforts to the current IPTp-SP policy [17].
Study objectives
The project is designed to develop a low-cost interven-
tion for pregnant women that will have an immediate
impact on the malaria burden in resource-limited coun-
tries. In this study, it is proposed to add an “extension”
strategy to the communities in rural areas in addition to
the standard IPTp-SP delivered through health facilities.
The novelty of this study is to bring health services closer
to where women live, using community health workers
(CHWs) to provide an antimalarial intervention to women
with difficult access to the formal health system. The
study will build on the use of CHWs who are already
managing malaria cases within the framework of commu-
nity case management of malaria (CCMm) [18].
The main aim is to establish whether maternal and infant
health can be improved by adding to existing IPTp-SP at
antenatal clinics (ANCs) community-scheduled screening
and treatment (CSST) for malaria among pregnant women
through CHWs. The study will test the primary hypothesis
that CSST plus IPTp-SP will reduce placental malaria
compared to IPTp-SP alone.
 Primary objective: To determine the protective
efficacy of CSST using CHWs against the primary
outcome of prevalence of placental malaria.
 Secondary objectives: To determine the protective
efficacy of CSST on maternal anaemia, maternal
peripheral infection, low birth weight, selection of
SP resistance markers, and on ANC attendance and
coverage of intermittent preventive treatment during
pregnancy.
These project objectives will be achieved through multi-
disciplinary research comprising clinical and bio-medical
research, health system research, socio-economic and
anthropological studies with a focus on CHW, involving
policy makers right from the start of the project as full
project partners (http://www.cosmicmalaria.eu).
Methods/designs
Study areas and participant eligibility
This is a multi-centre trial involving three countries with
varying malaria endemicity: low (The Gambia) versus high
transmission (Burkina Faso and Benin), and varying de-
grees of SP resistance (high in Benin [19] and moderate in
Gambia and Burkina Faso [20]). This will ensure that the
study outcomes would be broadly generalisable in order
to facilitate the formulation of recommendations for both
the West African region and other sub-Saharan countries.
The Gambia, a country where malaria transmission has
decreased to levels thought not possible a few years ago(and hence in a so-called “epidemiological transition”), will
provide information possibly applicable to countries that
may reach a similar status in the (near) future.
In The Gambia, the study is situated in the eastern
part of the country on the southern bank of the Upper
River Region (about 170,000 inhabitants). It will be
centred around the Basse Health Centre and satellite
health facilities. This is an area of seasonal malaria trans-
mission (July-December) that has recently experienced a
significant decline in malaria infections. Nevertheless,
malaria remains a significant problem with about 15% of
pregnant women with placental malaria at delivery as
detected by histopathology [9].
In Burkina Faso, the study is situated in the centre-west
of the country in the Nanoro health district catchment
area (about 145,000 inhabitants). Malaria transmission is
high and extremely seasonal and overlaps with the rainy
season (June-October).
In Benin, the study is situated at the Atlantic Region
in the southern part of the country, in the Glo-Djigbé,
Zinvié and Zè district communities (about 136,000 in-
habitants). Malaria transmission is perennial and the
main burden of the disease occurs during the two rainy
seasons (April-July and October-November).
The current treatment policy of uncomplicated mal-
aria in pregnancy is oral quinine but artemisinin-based
combination therapy (artemether-lumefantrine (AL)) may
be used in the second and third trimester of pregnancy for
all three countries, or amodiaquine-artesunate in Burkina
Faso and Benin [21-23].
All pregnant women resident in the study area and
willing to remain so until delivery will be invited to par-
ticipate. Women who have a history of sensitivity to sul-
phonamides and vulnerable persons (for example, the
mentally deficient) will be excluded. In The Gambia, preg-
nant adolescents younger than 16 years will not be en-
rolled unless consent is given by a responsible adult. In
Burkina Faso and Benin, a pregnant woman is considered
an adult if married (regardless of age). Study participants
are free to withdraw from the study at any time without
giving a reason.
Prior to the trial start, community sensitization and in-
volvement of village leaders will be carried out at each
study site. Appropriate community meetings will be held
where the trial will be explained to all community mem-
bers and consent at the community level to participate
from community leaders will be obtained. Individual
signed informed consent will also be obtained from all
participants.
Design
This is a multicenter, cluster-randomised controlled trial
in which the CHWs and related catchment population
(village/community) will be randomised to receive either
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current activities, that is IPTp-SP alone at health facil-
ities during ANC visits (Figure 1).
Study procedures
All communities
In principle, the first point of contact with pregnant
women is at the first ANC visit. Here, the study will be
explained to the woman and informed consent will be
obtained. If the woman is in the early stage of pregnancy,
she will be encouraged to return during her second tri-
mester for IPTp-SP. If the woman is in the second or third
trimester stage, health staff will give the first IPTp-SP dose
and plan the second one onto the ANC card at least
1 month after the first dose. A data collection form on
health and socio-demographic factors and a physical
examination will be carried out, and a blood slide and a
blood sample on filter paper will be collected for detection
of malaria infection and SP resistance markers (Figures 1
and 2). All women will be encouraged to deliver at the
health facility. If women do not attend the ANC, consent
will be obtained at village level.
Intervention communities
CHWs allocated to the intervention arm will follow spe-
cific training on community-based case management of
malaria, the need for monthly testing of pregnant women
using a rapid diagnostic test (RDT), and on issues related
to malaria in pregnancy, including the benefit of IPTp-SP
and administering SP as early as possible in the second tri-
mester of pregnancy.
The CHWs will continuously identify all pregnant
women in their own catchment area, visit eligible
women in their home and encourage them to attend
the ANC as early as possible in their pregnancy for enrol-
ment. The CHW will check after a week if the ANC was
visited. For women who do not attend the ANC, the
CHW will further encourage and discuss reasons for non-
attendance.
Thereafter, at monthly intervals up to the last week of
gestation, the CHW will revisit the study participant’s
house (Figure 2). The CHW will collect a blood slide
and a blood spot on filter paper, perform a RDT and ad-
minister a full course of AL to any woman with a posi-
tive RDT. In case of treatment, the CHWs will return to
assess uptake and compliance by administering a short
questionnaire and checking the empty packaging of the
treatment at the end of the course.
Control communities
In control communities, CHW will not be trained to ad-
minister RDT and AL to pregnant women. The womenwill be mainly followed through their attendance to the
health facilities at the ANC.
At time of delivery for all communities
The final study visit will occur at the time of delivery. A
blood sample will be collected just before delivery for
haemoglobin measurement as well for detection of mal-
aria infection and SP resistance markers and a short data
collection form on their current health status will be ad-
ministered. A placenta biopsy will be collected and all
newborns will be physically examined and weighed as
soon as possible after birth (Figures 1 and 2). Gestational
age will be estimated using the Ballard Score [24]. For
women not delivering at a health facility, study staff will
follow them up at home and will collect the same infor-
mation and biological samples as at the health facilities
as soon as possible.
Randomisation
The allocation of the two trial arms will be carried out
separately but consistently for each country. Prior to the
trial start, maps and population size of the study site in
all three countries will be obtained. CHWs who work in
villages with a population size of approximately 1,000 to
2,000 will be identified. If more clusters than required
are identified, the appropriate number of representative
clusters will be selected at random. Distance from the
centre of each village to the nearest IPTp-SP-providing
health facility will be calculated and used to group the
clusters into three categories. Stratification by these cat-
egories will ensure that the villages with the larger dis-
tances are evenly distributed between trial arms. The
balanced allocation of each cluster to a trial arm will be
done using a computer-based randomisation (StataCorp
LP, USA, http://www.stata.com).
Clinical data collection and patient treatments
At the antenatal clinic
All study participants returning to the ANC for scheduled
or unscheduled visits will undergo a health assessment by
study staff. In case of suspected malaria (fever, headache,
and so forth), a RDT test will be performed and, if positive,
AL administered.
Community health worker home visits in the intervention
arm only
RDT will be performed on a monthly basis for women
enrolled in the intervention arm regardless of the pres-
ence of malaria symptoms. If positive for malaria, treat-
ment will be given with AL. If the woman is severely ill
at time of visit (from malaria or other causes and/or
from complications from the pregnancy) she will be re-
ferred to the health facility for further care.
Figure 1 Schematic of study design. ANC, antenatal clinic; CHW, community health worker; CSST, community-scheduled screening and treatment;
FA, field assistant; IPTp-SP, intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine; RDT, rapid diagnostic test.
Figure 2 Schedule of events. Symbols are from thenounproject.com collection: ‘baby’ symbol (1), ‘baby’ symbol (2) by Edward Boatman, ‘house’
symbol by Marco Olgio, ‘medicine’ symbol by Emmanual Mangatia, ‘medicine’ symbol by Paulo Volkova, ‘doctor’ symbol by Paulo Volkova,
‘pointer’ symbol by Evan MacDonald and ‘drop’ symbol by Eric Bergholz. ANC, antenatal clinic; Hb, haemoglobin; IPTp; intermittent preventive
treatment during pregnancy.
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Haematology
Maternal haemoglobin will be measured using Hb301
Hemocue® (part of the Radiometer Group, Sweden) and
anaemia (haemoglobin <11 g/dL) diagnosed at the time
of delivery.
Peripheral malaria infection
Blood samples will be collected by finger pricks at speci-
fied time points during the trial for blood slides (thick
blood film) and blood spots on filter paper. Thick blood
smears will be stained with 3% Giemsa for 30 minutes
and read by trained microscopists at each site. Parasite
densities will be calculated by counting the number of
asexual parasites per 200 leukocytes (or per 500 leuko-
cytes if the count is <10 asexual parasites/200 leukocytes),
assuming a leukocyte count of 8,000/μl. A blood smear
will be considered negative when the examination of 100
high-power fields does not reveal asexual parasites. Each
slide will be read separately by two experienced microsco-
pists and discrepancies resolved by a third reader.
Blood spots on filter paper will be used for the molecu-
lar diagnosis of P. falciparum (to detect sub-patent infec-
tions) and the identification of SP resistance markers.
Placental malaria
A 1 cm2 biopsy specimen will be obtained from the
maternal-facing side of the placenta as soon as possible
after delivery. Biopsy specimens will be preserved in
10% neutral buffered formalin which will be processed
and embedded in paraffin wax by standard techniques.
Pending histological evaluation, all biopsies will be kept at
4°C. Paraffin sections 4 millimeters thick will be stained
with hematoxylin-eosin stain.
Placental biopsies will be classified according to the
following definitions [25]:
1. Acute infection (parasites present, malaria
pigment absent)
2. Chronic infection (parasites and malaria pigment
present)
3. Past infection (no parasites but pigment present)
4. No infection (both parasites and malaria pigment
absent)
Safety considerations
The risk of participating in this cluster randomized trial
is low. The World Health Organization recommends the
use of artemisinin-based combination therapy, in this
case AL, during the second and third trimester of preg-
nancy [26,27]. The subjects will not be exposed to any
danger or increased risk due to the conduct of the study.
There is the possibility of mild discomfort and bruising
at the site where blood is obtained. Collection of bloodsamples is part of the normal procedure in the diagnosis
of malaria and is considered not to be a medical risk
when adequately performed by a qualified health worker
(including CHWs). Placental biopsies will be obtained
after delivery, with no risk or discomfort for the neonate
or mother. Qualified personnel using appropriate dispos-
able equipment will collect blood samples and placental
biopsies.
CHWs in the intervention arm will be trained on safety
reporting requirements and on the recognition of danger
signs and serious adverse events (SAEs). In case of any
SAE of the pregnant woman, deterioration of her condi-
tion or reaction after the administration of the drug, the
CHW will report this immediately to the study staff who
will perform the necessary further assessments and refer-
rals to the appropriate health facilities if required.
During the course of the study, any important medical
events which occur will be appropriately recorded, man-
aged and reported. Midwives and/or research staff will rec-
ord all occurrences of adverse pregnancy outcomes such
as a miscarriage or spontaneous abortion (<28 weeks of
gestation), stillbirth (>28 weeks) or the occurrence of any
congenital malformation. All reported SAEs and important
medical events will be reported to the study site investiga-
tor or deputy. The local principal investigator will inform
the sponsor and the coordinating investigator. The sponsor
will inform the ethics committee and the Data Safety and
Monitoring Board.
Study endpoints
Primary endpoint
Prevalence of placental malaria (any category, including
past infection) determined by a placental biopsy taken
soon after delivery at a health facility.
Secondary endpoints
 Maternal anaemia (haemoglobin <11 g/dL) at
delivery
 Maternal P. falciparum peripheral infection
(microscopy and PCR) at delivery and during
pregnancy
 Low birth weight (<2,500 grams)
 IPTp-SP coverage by village/cluster
 SP resistance markers profiles
 Number of ANC visits during pregnancy
 Number of doses of IPTp-SP taken during
pregnancy
Sample size rationale
The study will test the primary hypothesis that CSST
plus IPTp-SP will reduce placenta malaria compared to
IPTp-SP alone. Sample size calculation was performed
according to Hayes and Bennett [28]. Based on available
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including past infection) is at least 15% in the three
study sites. Although the coefficient of variation for pla-
cental malaria is not known, it is set at 0.15 within each
country. It is assumed that the intervention will decrease
placental malaria by 30%, from 15% to 10.5%. Further-
more, the assumption is made that each CHW will recruit
at least 40 pregnant women per year, corresponding
roughly to a population of 800 people (assuming 5% of the
population is pregnant). Within each study site, the study
will be able to show a significant difference between inter-
vention and control groups with 15 clusters per arm at
80% power and at the 10% significance level. This trans-
lates to 45 clusters per arm across the three study sites.
Therefore, the total study population will be 5,400
women, 1,800 women in each country, and will require
an 18-month recruitment period in order to enrol at
least 60 women per cluster.
Data handling and record keeping
All data handling and record keeping will be standar-
dised across the three study sites. At the health facility,
all pregnant women will be recorded on a study register
held at each clinic. Women who are enrolled onto the
study will also be given a unique identity number.
A standardised data collection form on the health status,
medical history of the women, and socio-demographic
characteristics will be administered by health staff at the
time of enrolment at the health facility. A standardised
data collection form on current health status will then be
administered at subsequent ANC visits (intervention and
control arm) and at each monthly visit by the CHWs in
the intervention arm only. All data will be double entered
using OpenClinica® (www.openclinica.com) databases at
each site. Consistency checks will be performed and any
outliers and missing data points will be checked against
the original forms and subsequently amended in the data-
set. Errors including missing data that may have occurred
during the data collection will be reported with a mini-
mum delay for further investigation.
All names and addresses will be removed from the data
collection forms before data entry. The datasets will be
password protected and only accessed by the data man-
ager and local investigators at each study site. All sam-
ples will be labelled with the woman’s unique identity
number and date of collection. This will ensure anonymity
so all handlers of the specimens are blinded to the inter-
vention allocation.
Analytical plan
Appropriate summary statistics (that is, mean and stand-
ard deviation for normally distributed variables and me-
dian and inter-quartile range for non-normally distributed
variables) will be used to describe the baseline data.The primary analysis will compare the prevalence of
placental malaria (defined as number of positive samples
by total number of samples) between the intervention
and the control group.
Secondary analysis will compare the following vari-
ables between trial arms: (i) mean haemoglobin levels
and prevalence of anaemia (haemoglobin <11 g/dL) at
delivery, (ii) prevalence of P. falciparum peripheral in-
fection (microscopy and PCR) at delivery and during
pregnancy, (iii) mean birth weight and proportion of
newborns with low birth weight (<2,500 g) between the
two trial arms, (iv) level of ANC attendance by village/
cluster and coverage of IPTp-SP (defined by number of
doses completed during pregnancy), and (v) SP resist-
ance markers profiles.
For the primary and secondary analysis both linear re-
gression (for continuous outcomes such as haemoglobin
levels) and logistic regression (for binary outcomes such
as placental malaria) will be used to quantify the difference
between trial arms. The regression models will allow for
the multi-level structure of the data (that is, individuals
within villages) using random effects and for all relevant
co-variates to be taken into account. Model assumptions
will be checked to confirm reliable estimates.
Timetable of event
The recruitment of study subjects will last for 18 months.
The expected duration for each study subject is approxi-
mately 6 months - from enrolment during pregnancy up
to time of delivery. It is expected that the total duration
of the trial will be 24 months to allow the delivery of the
last recruited pregnant woman.
Ethical approval
Ethical approval by the Gambia Government/MRC labora-
tories Joint Ethics Committee was obtained on 25 June
2013 (ref SCC1336). Ethical approval by the Institutional
Ethics Committee of Centre Muraz in Burkina Faso was
obtained on 19 September 2013 (ref A20-2013/CE-CM).
Ethical approval by the Comité National d’Ethique pour la
Recherche en Santé in Benin was obtained on 9 December
2013 (No_0126/MS /DC/SGM /DFR /CNERS/SA).
Discussion
To reach successful global malaria control, there is an ur-
gent need to access those at greatest risk of malaria infec-
tion. IPTp-SP if given at least twice after the first trimester
has been shown to be effective in preventing malaria in-
fection and its consequences during pregnancy. However,
in the majority of sub-Saharan African countries, IPTp-SP
coverage is low, with only 22% of pregnant women re-
ceiving IPTp-SP [16]. Systematic screening of pregnant
women for malaria, and treating them if positive may
further reduce the burden of malaria in pregnancy. In
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ing by RDT at scheduled ANC visits and treating posi-
tive women was as effective as IPTp-SP [29]. However,
both interventions are currently being implemented
through health facilities and thus the health system es-
sentially waits for the women to attend a facility and
does not tackle the issue of low or untimely (late in
pregnancy) attendance. Further issues with delivery of
these interventions include: unclear policy and guidance
of IPTp-SP, stock outs at health facilities for both bed
nets and SP, and poor quality of care. Low IPTp-SP cover-
age was also associated with poor education, poor know-
ledge of malaria, socio-economic status and age [30]. In
rural areas, this is a major issue as pregnant women often
have limited access to health facilities due to distance,
poverty, low levels of education, strong traditional values,
limited access to information and poor road infrastructure
[31,32]. Long distances can be an actual barrier for attend-
ing a health facility but they can also be a deterrent to
seeking care [33].
In this study, it is proposed to add an “extension”
strategy to the communities in rural areas to the stand-
ard IPTp-SP delivered through the health facilities and
thus bring health services closer to where women live.
The study will build on the use of CHWs who are
already managing malaria cases within the framework
of CCMm [18]. At this level, RDTs for the diagnosis of
malaria are already being used or their implementation
is planned. CCMm supported by RDT is at various
stages of implementation; in The Gambia, the National
Malaria Control Program is planning to introduce na-
tionwide CCMm supported by RDT; in Burkina Faso,
CCMm has been implemented and is currently man-
aged by an international non-government organisation
(Plan International) and four local non-government
organisations under the supervision of the National
Malaria Control Program; in Benin, CCMm is part of
the National Malaria Policy, though it still needs to be
scaled up nationwide.
The study will extend the CCMm which at present is
primarily aimed at children under the age of 5 years to
pregnant women. The aim is to improve both IPTp-SP
coverage as CHWs encourage women to attend the
ANC for the IPTp at the right time, allow systematic
screening for malaria infection and provide an oppor-
tunity to treat malaria when the prophylactic effect of
IPTp-SP has waned. The trial will also investigate the
prevalence of SP resistance markers in the positive mal-
aria samples obtained during the study as it could be hy-
pothesized that the beneficial effects of the intervention
might be more pronounced in areas with high SP resist-
ance, because women could be more prone to placental
malaria when IPTp-SP has a reduced effect and, al-
though not yet observed in West Africa, extremely highlevels of SP resistance markers in the parasite population
may even lead to adverse effects of SP [34].
Trial status
At time of submission of this paper, ethical approval has
been obtained, and recruitment is ongoing in all three
study sites.
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